Tharimmune Inc. changed its corporate name to Canton Strategic Holdings, Inc. and began trading on Nasdaq under the new ticker CNTN, effective February 18 2026.
The rebrand signals a strategic shift toward the digital‑asset ecosystem. Canton Strategic Holdings will leverage Canton Coin and support the Canton Network’s institutional blockchain adoption, becoming the first publicly traded firm to do so while continuing its clinical‑stage biotechnology operations.
The company’s capital structure underpins this pivot: a $545 million private placement in November 2025, a $55 million underwritten registered offering in January 2026, and approval to operate as a Super Validator on the Canton Network. The board now includes former CFTC Commissioner Jill Sommers and DRW Chief of Staff William Wiley, adding regulatory and institutional expertise.
The hybrid model positions Canton Strategic Holdings to capture growth in both digital‑asset infrastructure and biotech research. The digital‑asset focus is expected to drive new revenue streams, while the biotech pipeline provides a long‑term, diversified growth engine.
The rebrand reflects confidence in the Canton Network’s potential to transform institutional finance, and the company’s recent capital raises and board appointments signal strong support for this strategic direction.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.